Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Everest Enters $224 Million Two-Drug China Partnership with Arena

publication date: Dec 5, 2017

Everest Medicines announced a $224 million partnership with San Diego's Arena Pharma to develop two Arena small molecule candidates in China and southeast Asia. Both candidates are in US clinical trials. Ralinepag is aimed at pulmonary arterial hypertension, and etrasimod is being tested in autoimmune diseases. Everest is a new company, dedicated to bringing innovative western drugs to China and backed with $50 million in an initial financing led by China's C-Bridge Capital. C-Bridge describes Everest as its incubator platform for bringing novel drugs to China. More details....

Stock Symbol: (NSDQ: ARNA)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China